title: [Susceptibility to rifabutin and novel fluoroquinolones in Mycobacterium avium complex isolates from patients with sputum culture-positive pulmonary disease who are undergoing standard chemotherapy].
abstract: We investigated the susceptibility to conventional and newer antimycobacterial agents including rifabutin (RBT) and novel fluoroquinolones (NFQs) among 48 clinical Mycobacterium avium complex (MAC) isolates from patients with sputum culture-positive MAC disease who were undergoing standard chemotherapy. RBT and NFQs were superior to conventional agents because of higher rates of susceptibility and lower minimum inhibitory concentration. NFQs showed cross-resistance among quinolones. In contrast, RBT did not show cross-resistance to RFP. Most clarithromycin-resistant or rifampicin-resistant cases were susceptible to RBT and NFQs. In conclusion, RBT and NFQs possess good in vitro antimicrobial activity among clinical isolates of culture-positive pulmonary MAC disease, which suggests that a combination of such microbiologically active agents may improve clinical effectiveness more than standard chemotherapy regimens.
authors.affiliation: Department of Internal Medicine, National Hospital Organization, Toneyama Hospital.
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Tateishi
authors.forename: Masaharu
authors.initials: M
authors.lastname: Motone
authors.forename: Kenji
authors.initials: K
authors.lastname: Yoshimura
authors.forename: Mari
authors.initials: M
authors.lastname: Miki
authors.forename: Keisuke
authors.initials: K
authors.lastname: Miki
authors.forename: Seigo
authors.initials: S
authors.lastname: Kitada
authors.forename: Hisako
authors.initials: H
authors.lastname: Hashimoto
authors.forename: Toru
authors.initials: T
authors.lastname: Hiraga
authors.forename: Ryoji
authors.initials: R
authors.lastname: Maekura
mesh_terms: D000904:Antibiotics, Antitubercular / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015269:Mycobacterium avium Complex / Q000187:drug effects* / Q000302:isolation & purification*; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy / Q000382:microbiology*; D017828:Rifabutin / Q000008:administration & dosage / Q000494:pharmacology*; D013183:Sputum / Q000382:microbiology*; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000382:microbiology*
chemical_list: D000904:Antibiotics, Antitubercular; D024841:Fluoroquinolones; D017828:Rifabutin